Bipolar Depression market in 7MM is expected to witness a major change in the study period 2019-2032

The Bipolar Depression market report provides current treatment practices, emerging drugs, Bipolar Depression (Manic Depression) market share of the individual therapies, current and forecasted Bipolar Depression market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Bipolar Depression treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Bipolar Depression market.

Key takeaways from the Bipolar Depression Market Report
• In the year 2020, the total diagnosed prevalent case of Bipolar Disorder (Manic Depression) was 3,552,076 cases in the 7MM.
• According to DelveInsight, the Bipolar Depression market in 7MM is expected to witness a major change in the study period 2019-2032.
• Bipolar Depression Market Companies are working such as Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways and others.
• Bipolar Depression Pipeline therapies such as cariprazine, NRX-101, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL) Extended Release, Quetiapine XR, Esketamine DPI - low dose, Lumateperone, Lithium carbonate, and others.

To read more about the latest drug development related to Bipolar Depression, get a snapshot of the key highlights included in the Bipolar Depression Market Outlook @ https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bipolar Depression Overview

Bipolar Depression, previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed). In manic episodes, a person can be delighted, irritable, and there is a marked increase in activity level, whereas, in depressive episodes, someone might feel sad, indifferent, or hopeless, in combination with a deficient activity level. Hypomanic episodes are also seen in patients, and it is a less severe form of mania. It is divided mainly into four subtypes BD-I, BD-II, cyclothymic disorder, and BD not otherwise specified (BD-NOS); the classification is based on the characteristics of mood swings.

Bipolar Depression Epidemiology Segmentation in the 7MM
• Bipolar Depression Patient Pool
• Bipolar Depression Treated Cases

To know more about the Bipolar Depression drugs market growth, get a snapshot of the report Bipolar Depression Market Analysis Report @ https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bipolar Depression Emerging Drugs

Lumateperone: Intra-Cellular Therapies

Lumateperone is a novel second-generation antipsychotic drug. It is marketed under the brand name Caplyta for the treatment of schizophrenia in adults. Lumateperone is in preregistration for the treatment of Bipolar Depression. In May 2022, Intra-Cellular Therapies announced that the US FDA had accepted for review its supplemental New Drug Applications (sNDAs) for lumateperone, for the treatment of depressive episodes associated with bipolar I or II disorder (Bipolar Depression) as monotherapy and as adjunctive therapy with lithium or valproate. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 17, 2022 for the applications.

Zuranolone: SAGE Therapeutics

Zuranolone is an investigational oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). The drug is in Phase II clinical studies for the treatment of Bipolar Depression.

Bipolar Depression Market Outlook

The Bipolar Depression market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Bipolar Depression market trends by analyzing the impact of current Bipolar Depression therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

Read more about the Bipolar Depression treatment market report @
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Bipolar Depression Market Research Report
• Coverage- 7MM
• Study Period- 2019-2022
• Forecast Period- 2022-2032
• Bipolar Depression Companies- Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways and others.
• Bipolar Depression Pipeline Therapies- cariprazine, NRX-101, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL) Extended Release, Quetiapine XR, Esketamine DPI - low dose, Lumateperone, Lithium carbonate, and others.
• Bipolar Depression Market Drivers and Barriers

Table of Content
1. Key Insights
2. Bipolar Depression Executive Summary
3. Bipolar Depression Competitive Intelligence Analysis
4. Bipolar Depression Market Overview at a Glance
5. Bipolar Depression (Manic Depression): Disease Background and Overview
6. Patient Journey
7. Bipolar Depression (Manic Depression) Epidemiology and Patient Population
8. Bipolar Depression Treatment Algorithm, Current Treatment, and Medical Practices
9. Bipolar Depression Unmet Needs
10. Key Endpoints of Bipolar Depression Treatment
11. Bipolar Depression Marketed Products
12. Bipolar Depression (Manic Depression) Emerging Therapies
13. Bipolar Depression (Manic Depression): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Bipolar Depression Market Outlook
16. Access and Reimbursement Overview of Bipolar Depression (Manic Depression)
17. Bipolar Depression KOL Views
18. Bipolar Depression Market Drivers
19. Bipolar Depression Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Learn more about the Bipolar Depression Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.